Synergistic effects of the sesquiterpene lactone, EPD, with cisplatin and paclitaxel in ovarian cancer cells

• Main Authors: Van Haaften, C, Boot, A, Corver, W.E, Van Eendenburg, J.D, Trimbos, B.J, Van Wezel, T
• Other Authors: DUKE-NUS MEDICAL SCHOOL
• Format: Article
• Published: 2020
• Subjects: caspase 3; cisplatin; dye; eremophila 1(10) 11(1230)dien 12,8beta olide; paclitaxel; presto blue; sesquiterpene lactone derivative; unclassified drug; antineoplastic agent; lactone; sesquiterpene; apoptosis; Article; cancer resistance; cell specificity; cell viability; controlled study; drug cytotoxicity; drug efficacy; drug potentiation; drug selectivity; female; flow cytometry; G2 phase cell cycle checkpoint; human; human cell; in vitro study; incubation time; JC cell line; JC pl cell line; ovarian cancer cell line; ovary cancer; OVCAR 3 cell line; priority journal; SK OV 3 cell line; skin fibroblast; Ovarian Neoplasms; pathology; tumor cell line; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; Drug Synergism; Female; Humans; Lactones; Paclitaxel; Sesquiterpenes
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/174127
• Institution: National University of Singapore

10.1186/s13046-015-0157-2